JonesTrading has commenced coverage of Evaxion A/S (NASDAQ:EVAX), issuing a buy rating along with a price target of $10.00. This announcement came in a research report released on Tuesday morning, as reported by Benzinga. The initiation by JonesTrading adds to a growing focus on Evaxion’s stock, which has seen various analysts express their views in recent days.
Analyst Ratings and Price Targets
In the past week, several investment firms have provided insights into Evaxion A/S. Notably, Lake Street Capital adjusted its price target for the company from $11.00 to $9.00, while maintaining a buy rating. Additionally, Maxim Group began coverage on February 19, 2024, also assigning a buy rating with a price objective of $10.00.
HC Wainwright reaffirmed their buy rating and set a target price of $16.00 for Evaxion’s shares, reflecting confidence in the company’s potential. Conversely, Weiss Ratings issued a sell rating on January 9, 2024, categorizing the stock with a rating of “sell (d-)”. Overall, five analysts have given Evaxion a buy rating, while one has advised selling, leading to an average rating of “Moderate Buy” according to MarketBeat.com, with an average price target of $11.00.
Recent Financial Performance and Institutional Interest
Evaxion A/S recently reported its quarterly earnings on March 5, 2024, revealing earnings per share (EPS) of $0.30. Analysts project that the company will post an EPS of -0.15 for the current fiscal year. This performance has drawn interest from institutional investors, who have adjusted their holdings in Evaxion.
In the fourth quarter, Wesbanco Bank Inc. acquired a new stake valued at $48,000, while Northwestern Mutual Wealth Management Co. invested $38,000. SmartHarvest Portfolios LLC also entered the market, purchasing shares worth $72,000. Currently, institutional investors hold approximately 11.04% of Evaxion’s stock.
Company Overview and Future Prospects
Founded and headquartered in Copenhagen, Denmark, Evaxion A/S is a clinical-stage biotechnology company specializing in immunotherapies and vaccines, utilizing a proprietary AI-driven computational immunology platform. By leveraging machine learning and deep learning algorithms, the firm aims to identify and optimize antigen targets for therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.
The core of Evaxion’s operations lies in its AI platform, which analyzes extensive datasets of genomic, proteomic, and immunological information to predict immune-stimulating epitopes. This innovative approach places the company at the forefront of biotechnology, as it seeks to address significant health challenges through advanced technology.
As interest from investors continues to grow, the future of Evaxion A/S may hinge on its ability to deliver on its ambitious goals in the competitive biotechnology landscape.
